Merck KGaA Licenses CRISPR Gene-Editing Technology to Evotec
November 12 2019 - 8:53AM
Dow Jones News
By Kim Richters
Germany's Merck KGaA (MRK.XE) said Tuesday that it signed a
licensing agreement to grant Evotec SE (EVT.XE) access to its
CRISPR genome-editing technology.
The German biotechnology company will use Merck's gene-editing
technology to research, test and develop new drugs, the company
said.
The science and technology company didn't comment on financial
terms of the deal.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
November 12, 2019 08:38 ET (13:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024